Literature DB >> 7666590

Primary pulmonary lymphoma: relationship between clinical features and pathologic findings in 24 cases. The Japan National Chest Hospital Study Group for Lung Cancer.

A Tamura1, H Komatsu, N Yanai, J Homma, A Nagase, E Nemoto, T Hirai, T Hashizume, K Kawata, S Ishikawa.   

Abstract

To elucidate the relationship between the clinical features and pathologic findings of primary pulmonary lymphoma, we reviewed 24 patients with this disease. The pulmonary lymphomas were divided into four groups: (1) B-cell lymphoma composed of small to medium-sized lymphoid cells (19 cases); (2) B-cell lymphoma composed of large lymphoid cells (three cases); (3) T-cell lymphoma (one case); (4) malignant lymphoma of lymphomatoid granulomatosis (LYG) type (one case). Radiographs of the first group revealed a predominance of infiltration associated with ill-defined tumor margins upon gross pathology, corresponding histologically to lymphangitic spread. Air bronchogram and pleural tail or abutment were additional radiographic features. Characteristics of the second group were a nodule or mass evident on radiographs and well-circumscribed tumor margins upon gross pathology. Lack of air bronchogram was an another radiographic feature in this group. Seventeen patients in these two groups underwent complete resection of the tumors and survived without recurrence, whereas four received chemotherapy after biopsy and survived with disease. These results indicate that primary pulmonary B-cell lymphoma is a low-grade malignancy and that complete resection is the only therapy which leads to cure. In a single patient with T-cell lymphoma, the radiographic and pathologic features of the tumor were indistinguishable from those in the first group, but the patient had an unfavorable prognosis. We consider that, from a prognostic viewpoint, it is important to determine the T- or B-immunophenotype of the tumor cells for diagnosis of primary pulmonary lymphoma. The only patient in this series with pulmonary lymphoma of LYG type showed distinctive clinicopathologic findings. We consider that this uncommon disease should be separated from other types of primary pulmonary lymphoma.

Entities:  

Mesh:

Year:  1995        PMID: 7666590

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

Review 1.  Forty years literature review of primary lung lymphoma.

Authors:  Haralabos Parissis
Journal:  J Cardiothorac Surg       Date:  2011-03-03       Impact factor: 1.637

2.  Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL).

Authors:  Maopeng Yang; Shu Zhao; Xaiosan Zhang; Xiaohong Wang; Minghui Zhang; Yan Wang; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2012-08-09

Review 3.  NK/T cell lymphoma of the lung: a case report and review of literature.

Authors:  P Laohaburanakit; K A Hardin
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

4.  Primary extranodal NK/T-cell lymphoma of the lung: Mimicking bronchogenic carcinoma.

Authors:  Chia-Hsin Liu; Hong-Hau Wang; Cherng-Lih Perng; Chung-Kan Peng; Chih-Feng Chian; Chih-Hao Shen
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

5.  Identification of genuine primary pulmonary NK cell lymphoma via clinicopathologic observation and clonality assay.

Authors:  Li Gong; Long-Xiao Wei; Gao-Sheng Huang; Wen-Dong Zhang; Lu Wang; Shao-Jun Zhu; Xiu-Juan Han; Li Yao; Miao Lan; Yan-Hong Li; Wei Zhang
Journal:  Diagn Pathol       Date:  2013-08-19       Impact factor: 2.644

6.  Primary pulmonary non-Hodgkin's lymphoma: a retrospective analysis of 29 cases in a Chinese population.

Authors:  Jiajia Huang; Tongyu Lin; Zhi-Ming Li; Ruihua Xu; Huiqiang Huang; Wenqi Jiang
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

Review 7.  Approach to Peribronchovascular Disease on CT.

Authors:  Jane P Ko; Francis Girvin; William Moore; David P Naidich
Journal:  Semin Ultrasound CT MR       Date:  2018-12-20       Impact factor: 1.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.